Nucleolin malonylation as a nuclear-cytosol signal exchange mechanism to drive cell proliferation in Hepatocarcinoma by enhancing AKT translation
Year: 2024
Type: article
Abstract: Cancer cells undergo metabolic reprogramming that is intricately linked to malignancy. Protein acylations are especially responsive to metabolic changes, influencing signal transduction pathways and fostering cell proliferation. However, as a novel type of acylations, the involvement of malonylation in cancer remains poorly understood. In this study, we observed a significant reduction in malonyl-CoA levels in hepatocellular carcinoma (HCC), which correlated with a global decrease in malonylation. Subsequent nuclear malonylome analysis unveiled nucleolin (NCL) malonylation, which was notably enhanced in HCC biopsies. we demonstrated that NCL undergoes malonylation at lysine residues 124 and 398. This modification triggers the translocation of NCL from the nucleolus to nucleoplasm and cytoplasm, binding to AKT mRNA, and promoting AKT translation in HCC. Silencing AKT expression markedly attenuated HCC cell proliferation driven by NCL malonylation. These findings collectively highlight nuclear signaling in modulating AKT expression, suggesting NCL malonylation as a novel mechanism through which cancer cells drive cell proliferation.
Source: Journal of Biological Chemistry
Authors: Liang Sun, Hanjing Meng, Tao Liu, Qiong Zhao, Mingyi Xia, Zhongjun Zhao, Yuting Qian, Hao Cui, Xuefei Zhong, Keli Chai, Yang Tian, Yang Sun, Bao Zhu, Jiehui Di, Guanghou Shui, Lianjun Zhang, Junnian Zheng, Shutao Guo, Yong Liu
Institutions: Nankai University, State Key Laboratory of Medicinal Chemical Biology, Chinese Academy of Sciences, Institute of Genetics and Developmental Biology, State Key Laboratory of Molecular Developmental Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou Institute of Systems Medicine, Xuzhou Medical College, Affiliated Hospital of Xuzhou Medical College
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,800
Awards: G4924335280, G527322386, G8313627189
OpenAlex ID: W4402630196
